LobbyingGlobal Health Investment lobbying by quarter
Global Health Investment's latest lobbying report covers Q1 2026, at $40K. The four quarters Q4 2025–Q3 2026 total $80K. Its first report covers Q4 2025; the issues it reports most are Medical/Disease Research/Clinical Labs.
Global Health Investment
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $80K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $40K | 1 |
| Q1 2026 | $40K | 1 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Medical research and clinical labs$80K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| SL Strategies | $80K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MARY MOODY JOHNSON | U.S. Senate Committee on Health, Education, Labor and Pensions | Q1 2026 |
| SARA LOVE RAWLINGS | U.S. Senate Committee on Appropriations | Q1 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 05/04for Q1 | SL Strategies | $40K |
| 01/23for Q4 2025 | SL Strategies | $40K |
| 01/20for Q3 2025 | SL Strategies | Under $5,000 |